Literature DB >> 30059372

Stevens-Johnson Syndrome: A Challenging Diagnosis.

Wesley D Davis1, Phillip A Schafer.   

Abstract

Stevens-Johnson syndrome is a rare, yet life-threatening, delayed-type hypersensitivity reaction characterized by mucocutaneous epidermal necrolysis. Toxic epidermal necrolysis is a severe manifestation of Stevens-Johnson syndrome, defined as greater than 30% skin detachment. Stevens-Johnson syndrome with toxic epidermal necrolysis is characterized as an adverse cutaneous drug reaction and is associated with the use of sulfonamides, antiepileptics, and some classes of nonsteroidal anti-inflammatory drugs. The case presented in this report is that of a 17-year-old female who presented to her primary care provider with a chief complaint of headache; she was initially diagnosed with a urinary tract infection and prescribed nitrofurantoin (Macrobid). Over the next 2 days, her symptoms worsened, she presented to the emergency department twice, and was transferred to a burn unit for definitive care. This case highlights the importance of prompt identification and diagnosis of Stevens-Johnson syndrome and underscores the need for emergency providers to have a comprehensive knowledge of adverse cutaneous drug reactions.

Entities:  

Mesh:

Year:  2018        PMID: 30059372     DOI: 10.1097/TME.0000000000000197

Source DB:  PubMed          Journal:  Adv Emerg Nurs J        ISSN: 1931-4485


  2 in total

Review 1.  Clinical Manifestations and Genetic Influences in Sulfonamide-Induced Hypersensitivity.

Authors:  Pungki Afifah Asyraf; Ivanna Fauziyah Kusnadi; Jonathan Stefanus; Miski Aghnia Khairinisa; Rizky Abdulah
Journal:  Drug Healthc Patient Saf       Date:  2022-07-21

Review 2.  Lamotrigine and Stevens-Johnson Syndrome Prevention.

Authors:  Amber N Edinoff; Long H Nguyen; Mary Jo Fitz-Gerald; Erin Crane; Kyle Lewis; Samantha St Pierre; Alan D Kaye; Adam M Kaye; Jessica S Kaye; Rachel J Kaye; Sonja A Gennuso; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2021-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.